BeOne culls five cancer programs and an autoimmune Phase 2
BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experimental medicines as ...
May 6, 2026 02:22 PM EDT R&DPharma BeOne culls five cancer programs and an autoimmune Phase 2 Kyle LaHucik Biotech Correspondent BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that